Given the prevalence of hematological conditions, surgeries, and trauma incidents, hemostats—therapeutics designed to control and arrest bleeding—are an important tool in patient care. The prophylactic and therapeutic use of hemostats markedly enhances survival rates and improves the overall quality of life of patients suffering from these conditions. Since their inception in the 1960s, hemostats have witnessed remarkable progress in terms of the active ingredients utilized, therapeutic outcomes, demonstrated efficacy, and the storage stability. In this review, we provide a comprehensive analysis of commercially available hemostats approved by the FDA, along with newer investigative hemostats currently in active clinical trials. We delve into the modality of active ingredients, route of administration, formulation type, and disease indications of these approved and investigative hemostats. Further, we analyze the trends observed in the hemostat actives for Hemophilia A and B, concluding with insights into the emerging patterns and noteworthy developments to watch for in this dynamic field.

中文翻译：

---

 诊所中的止血钳


鉴于血液病、手术和创伤事件的普遍性，止血剂（旨在控制和阻止出血的疗法）是患者护理的重要工具。止血药的预防和治疗使用显着提高了生存率并改善了患有这些疾病的患者的整体生活质量。自 1960 年代问世以来，止血钳在使用的活性成分、治疗结果、已证明的疗效和储存稳定性方面取得了显着进步。在这篇综述中，我们对 FDA 批准的市售止血钳以及目前正在进行临床试验的新型研究止血钳进行了全面分析。我们深入研究了这些已批准和研究性的止血剂的活性成分模式、给药途径、配方类型和疾病适应症。此外，我们分析了在血友病 A 和 B 的止血活性物质中观察到的趋势，最后深入了解了这一动态领域中需要注意的新兴模式和值得注意的发展。